Co-Diagnostics

Co-Diagnostics CROIC

The Cash Return on Invested Capital (CROIC) of Co-Diagnostics (CODX) as of Oct 21, 2026 is -136.46 %. In the previous year, Cash Return on Invested Capital (CROIC) was -52.96 % — a change of 157.66% (lower).

CROIC

-136.46 %

YoY

157.66%

Last updated:

Cash Return on Invested Capital (CROIC) of Co-Diagnostics is 2025 -136.46 % . Cash Return on Invested Capital (CROIC) of Co-Diagnostics was 2024 -52.96 % . It decreases by 157.66% lower compared to the previous year.

The Co-Diagnostics CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-485.00 USD
Jan 1, 2019
-324.55 USD
Jan 1, 2020
41.07 USD
Jan 1, 2021
28.75 USD
Jan 1, 2022
4.48 USD
Jan 1, 2023
-26.34 USD
Jan 1, 2024
-52.96 USD
Jan 1, 2025
-136.46 USD
The Co-Diagnostics CROIC history
YEARCROICYoY
-136.46 %+157.66%
-52.96 %+101.03%
-26.34 %-688.59%
4.48 %-84.43%
28.75 %-29.99%
41.07 %-112.65%
-324.55 %-33.08%
-485.00 %+459.02%
-86.76 %-73.83%
-331.55 %-127.32%
1,213.77 %-279.55%
-675.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Cash Return on Invested Capital (CROIC) of Co-Diagnostics is -136.46 % in 2025.

Cash Return on Invested Capital (CROIC) of Co-Diagnostics changed from -52.96 % to -136.46 %, representing a 157.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Co-Diagnostics

All Key Metrics — Co-Diagnostics